Current treatment status-Undergoing active treatment-No response Page 2 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-No response Posts on Medivizor

Searching for patients with triple negative breast cancer to test this new treatment combination

Posted by on May 19, 2019 in Breast cancer | 0 comments

In a nutshell This trial is examining the safety and effectiveness of combination therapy with pembrolizumab (Keytruda) and lenvatinib (Lenvima) for triple negative breast cancer (TNBC) and other solid tumors. The main outcome to be measured will be the objective response rate (ORR; the percentage of participants who have complete...

Read More

Is combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?

Posted by on May 18, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients.  Some background Patients with NHL are often treated with targeted therapies....

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).   This study concluded that this combination appears safe and effective for these patients.   Some background Patients...

Read More

Evaluating chemotherapy regimens before stem cell transplantation for patients with non-Hodgkin’s lymphoma

Posted by on Apr 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...

Read More

Inotuzumab ozogamicin for patients with relapsed/unresponsive acute lymphoblastic leukemia

Posted by on Apr 24, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia.   This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...

Read More

Searching for patients to try a new combination of treatments for relapsed or unresponsive Hodgkin lymphoma.

Posted by on Apr 22, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...

Read More

Optimal treatment for relapsed and unresponsive nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Apr 18, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...

Read More

Evaluating long-term outcomes after radiation and stem cell transplantation for recurrent or unresponsive Hodgkin lymphoma

Posted by on Apr 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...

Read More

FOLFIRI plus aflibercept in the treatment of metastatic colorectal cancer outside of clinical trials

Posted by on Mar 29, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of the combined treatment FOLFIRI with aflibercept (Zaltrap) outside of clinical trials in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment might be a safe second line option in patients who progressed after first-line...

Read More

Looking for patients with relapse/unresponsive lymphoma to test a treatment combination

Posted by on Mar 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...

Read More

Evaluating PD-1 inhibitors for patients with Hodgkin lymphoma in a real-world setting

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of PD-1 inhibitors for patients with classical Hodgkin lymphoma (cHL) outside of clinical trials. This study concluded that PD-1 inhibitors are safe and effective for these patients. Some background Standard first-line chemotherapy is highly effective in treating 70 – 80% of...

Read More